Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis

Key Information
Source
Journal of the American College of Cardiology
Year
2015
summary/abstract

Transthyretin amyloidosis is a fatal disorder that is characterized primarily by progressive neuropathy and cardiomyopathy. It occurs in both a mutant form (with autosomal dominant inheritance) and a wild-type form (with predominant cardiac involvement). This article guides clinicians as to when the disease should be suspected, describes the appropriate diagnostic evaluation for those with known or suspected amyloidosis, and reviews the interventions currently available for affected patients.

Abstract Source
https://www.ncbi.nlm.nih.gov/pubmed/26610878
Full Text Source
https://www.sciencedirect.com/science/article/pii/S0735109715067881?via%3Dihub
DOI
10.1016/j.jacc.2015.09.075
Authors
Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G
Organisation
Mayo Clinic, USA; Indiana University School of Medicine, USA; Mayo Clinic, USA; Hospital de Santo Antonio, Portugal; Federal University of Rio de Janeiro of Brazil, Brazil; Boston University School of Medicine, USA; University Hospital Henri Mondor, France; Universitätsklinikum Münster, Germany; University of Pavia, Italy